Jazz Pharmaceuticals has agreed to buy GW Pharmaceuticals for $7.2 billion through a combination of cash and equity. The product diversification from the merger is expected to result in double-digit revenue growth and to be accretive in the first full year of operations. Shares of GW are up substantially while Jazz shares have slipped slightly.
Menu